Darwin Global Management, Ltd. Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001839209

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidFocusedHealth TiltHigh Turnover how tags are computed

Q3 2026 · 5 positions · Total reported value $3.99B · Top-10 concentration 100.0% · Updated 2026-11-17

Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR

Turnover: 33.3% · 1 new · 0 cut · 1 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

In its Q3 2026 13F filing, Darwin Global Management, Ltd. disclosed 5 equity positions with a combined reported value of $3.99B. The filing implies a focused portfolio: its ten largest positions account for 100.0% of reported value. HoldingsHub classifies the profile as Mid / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q3 2026 were RVMD ($2.18B), GMAB ($638.58M), BLTE ($525.95M). By sector, the heaviest allocations are Health Care 100.0%.

Versus the prior quarter, Darwin Global Management, Ltd. opened 1 new positions, trimmed 0 and fully exited 1, a turnover rate of 33.3% of positions. The portfolio's overlap with the prior quarter was 67% of names.

The largest new positions opened in Q3 2026 were GMAB ($638.58M).

Of the 1 positions fully exited versus the prior quarter, the largest were INSM ($673.60M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q3 2026)

  • GMAB GENMAB A/S · $638.58M

Fully Exited (vs previous quarter)

  • INSM INSMED INC · prev qtr: $673.60M

Insider Transactions (Form 4)

Latest Darwin Global Management, Ltd. buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Darwin Global Management, Ltd. is an SEC-registered 13F filer. As of Q3 2026 it reported 5 US equity positions with a combined value of $3.99B. HoldingsHub carries 13 quarters of its filings (Q3 2023–Q3 2026).

Portfolio Structure

  • 5 positions · $3.99B reported value (Q3 2026)
  • Top 10 holdings = 100.0% of reported value
  • Largest position: RVMD (REVOLUTION MEDICINES INC) at 54.7%
  • Average position size: $798.28M

Sector Tilt

  • Health Care 100.0%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q3 2026: 1 new, 2 added, 1 exited
  • 2 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

AI Rebalance Analysis

1. Overall direction and market view: The fund increased exposure to biotech/healthcare (84% of top-10 holdings), with a new position (GMAB) and additions to existing names (BLTE, ABVX), suggesting a bullish view on healthcare innovation. 2. Key moves: - New: GMAB (16.00% weight, 17.9M shares). - Added: BLTE (wt +1.04%, shares +0.6%), ABVX (wt +0.72%, shares +11.0%). - No reductions (per action field). 3. Portfolio structure: Active, concentrated in healthcare (biotech/pharma), high-risk (small/mid-cap biotechs), with a contrarian tilt (e.g., ABVX, BLTE). 4. Per-holding one-liner: - RVMD: Revolution Medicines (oncology drug developer). - GMAB: Genmab A/S (biotech, antibody therapeutics). - BLTE: Belite Bio (retinal disease treatments). - ABVAX: Abivax (hepatitis B/immunology). - ROIV: Roivant Sciences (targeted drug discovery). 5. Style summary: Aggressive biotech focus with new bets and incremental adds, leveraging healthcare innovation themes.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice. · AI generated 2026-11-17 09:47

Sector Allocation

Health Care 100.0%
Sort by: Value · CSV
# Shares Value Weight Allocation Change
1 10.63M $2.18B 54.66%
54.66%
Hold
2 17.90M $638.58M 16.00%
16.00%
New
3 3.10M $525.95M 13.18%
13.18%
Add
4 4.02M $398.22M 9.98%
9.98%
Add
5 6.75M $246.75M 6.18%
6.18%
Hold

FAQ

What did Darwin Global Management, Ltd. buy in 2026-Q3?

In its 2026-Q3 13F filing, Darwin Global Management, Ltd. reported 5 equity positions worth $3.99B in aggregate; its largest disclosed positions were RVMD ($2.18B), GMAB ($638.58M), BLTE ($525.95M).

How large is Darwin Global Management, Ltd.'s portfolio?

Darwin Global Management, Ltd. reported $3.99B of long equity holdings across 5 positions as of 2026-Q3. Top-10 holdings account for 100.0% of reported value.

What is Darwin Global Management, Ltd.'s investment style?

HoldingsHub classifies the portfolio as Mid / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/darwin-global-management/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →